Other languages Basilea Pharmaceutica AG

Equities

BSLN

CH0011432447

Market Closed - Swiss Exchange Other stock markets 11:30:41 2024-05-31 am EDT			5-day change	1st Jan Change
43.7 ^CHF	+0.23%		-0.46%	+23.80%

May. 16	Basilea Pharmaceutica Receives Milestone Payment from Pfizer for Cresemba Sales	MT
May. 16	Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Basilea Pharmaceutica Receives Milestone Payment from Pfizer for Cresemba Sales	May. 16
Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	May. 16
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	May. 16
Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024	May. 03
Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024	May. 03
Basilea shareholders approve all proposals of the board of directors at the annual general meeting	Apr. 24
Basilea shareholders approve all proposals of the board of directors at the annual general meeting	Apr. 24
Actym Therapeutics Appoints Thomas Smart as CEO	Apr. 24
Basilea Pharmaceutica Receives Grant for Antibiotics Program	Apr. 09
Basilea Pharmaceutica : Updated April 9, 2024	Apr. 09
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics	Apr. 09
Stocks Close in Green as Swiss Inflation Unexpectedly Slows	Apr. 04
European stocks rise ahead of inflation data; Basilea shines	Apr. 04
Basilea Pharmaceutica : Updated April 4, 2024	Apr. 04
Basilea announces US FDA approval of antibiotic ZEVTERA(R) (ceftobiprole medocaril) for three indications	Apr. 04
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications	Apr. 04
US FDA Greenlights Basilea Pharmaceutical's Treatment for Bloodstream Infections	Apr. 04
US FDA approves Basilea Pharmaceutica's antibiotic	Apr. 03
US FDA approves Basilea Pharmaceutica's antibiotic	Apr. 03
Basilea Pharmaceutica : Updated April 3, 2024	Apr. 03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Basilea Pharmaceutica AG

Equities

BSLN

CH0011432447

Other languages

Filters